by Madaline Spencer | Jun 26, 2026
Eunice S. Wang, MD, Chief of Leukemia at Roswell Park Comprehensive Cancer Center, discusses long-term results of ziftomenib in combination with venetoclax and azacitidine in patients with acute myeloid leukemia (AML). AML is a cancer that affects the...
by Madaline Spencer | Jun 25, 2026
A study published in The Lancet Hematology evaluated the efficacy and safety of deucrictibant for the on-demand treatment of hereditary angioedema (HAE) attacks. Hereditary angioedema (HAE) is a rare condition characterized by recurrent episodes of severe swelling of...
by Madaline Spencer | Jun 25, 2026
Saad Usmani, MD, Hematologist-Oncologist at Memorial Sloan Kettering Cancer Center, discusses results from the CEPHEUS clinical trial of daratumumab combination therapy in patients with newly diagnosed multiple myeloma (MM). MM is a rare blood cancer...
by Madaline Spencer | Jun 24, 2026
A study published in Nature Medicine evaluated whole-exome sequencing data from the DECLARE-TIMI 58 clinical trial to determine whether sodium–glucose cotransporter 2 (SGLT2) inhibition is beneficial to patients with rare variants in cardiomyopathy-associated genes....
by Madaline Spencer | Jun 24, 2026
Fatima Scipione, Vice President of Global Patient Affairs at Blueprint Medicines, discusses the Colors of SM program. Systemic mastocytosis (SM) is a rare disease usually caused by mutations of the KIT D816V gene. The disorder is characterized by...
